Vontobel Holding Ltd. Takes Position in Seres Therapeutics, Inc. (NASDAQ:MCRB)

Vontobel Holding Ltd. purchased a new position in Seres Therapeutics, Inc. (NASDAQ:MCRB) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 394,826 shares of the biotechnology company’s stock, valued at approximately $374,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Vanguard Group Inc. increased its holdings in Seres Therapeutics by 12.1% during the 1st quarter. Vanguard Group Inc. now owns 6,734,821 shares of the biotechnology company’s stock worth $5,213,000 after purchasing an additional 729,514 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Seres Therapeutics in the 1st quarter valued at $39,000. Virtu Financial LLC purchased a new position in shares of Seres Therapeutics in the 1st quarter valued at $73,000. Point72 DIFC Ltd purchased a new position in shares of Seres Therapeutics in the 2nd quarter valued at $64,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Seres Therapeutics in the 2nd quarter valued at $92,000. 59.34% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on MCRB. StockNews.com downgraded Seres Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, August 13th. Chardan Capital reiterated a “buy” rating and issued a $1.25 price target on shares of Seres Therapeutics in a report on Wednesday, August 14th. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $10.00 price target on shares of Seres Therapeutics in a report on Friday, September 13th.

Insider Transactions at Seres Therapeutics

In related news, insider Teresa L. Young sold 24,480 shares of the company’s stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $1.08, for a total value of $26,438.40. Following the completion of the transaction, the insider now owns 78,178 shares of the company’s stock, valued at approximately $84,432.24. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have sold 28,844 shares of company stock worth $30,104 over the last quarter. 5.10% of the stock is currently owned by insiders.

Seres Therapeutics Price Performance

Seres Therapeutics stock opened at $0.78 on Wednesday. The stock has a market capitalization of $118.51 million, a price-to-earnings ratio of -1.30 and a beta of 2.03. Seres Therapeutics, Inc. has a 1-year low of $0.54 and a 1-year high of $2.05. The business has a fifty day moving average price of $0.90 and a 200-day moving average price of $0.92.

Seres Therapeutics (NASDAQ:MCRB) last issued its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.08. During the same period last year, the firm posted $0.36 EPS. On average, equities research analysts anticipate that Seres Therapeutics, Inc. will post -0.95 earnings per share for the current fiscal year.

Seres Therapeutics Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.